Boswellic acids, the active components of Boswellia serrata (Indian frankincense), have traditionally been used in Ayurvedic medicine for a variety of neurological and inflammatory conditions. The potential use of boswellic acid in epilepsy is supported by a small number of preclinical (animal) studies suggesting anticonvulsant properties. For example, studies in rodents have shown that extracts of Boswellia serrata and isolated boswellic acids may reduce seizure frequency and severity, possibly by modulating neuroinflammation, oxidative stress, and neurotransmitter balance. One proposed mechanism is the inhibition of 5-lipoxygenase, leading to reduced leukotriene synthesis and neuroinflammation, which are implicated in the pathophysiology of epilepsy.

However, there is a lack of robust clinical evidence in humans. No large-scale randomized controlled trials have evaluated boswellic acid as a treatment or adjunct in epilepsy. Most evidence comes from animal models or in vitro studies. Some traditional systems may reference its use for general neurological health, but direct historical use for epilepsy is less well documented compared to other botanicals. In summary, while preliminary scientific data suggest potential benefit, current evidence is limited and insufficient to recommend boswellic acid as a proven therapy for epilepsy. Further research, especially in human subjects, is needed.